NASDAQ
ABVC

ABVC Biopharma Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

ABVC Biopharma Inc Stock Price

Vitals

Today's Low:
$1.07
Today's High:
$1.18
Open Price:
$1.07
52W Low:
$0.5
52W High:
$3.13
Prev. Close:
$1.07
Volume:
21548

Company Statistics

Market Cap.:
$21.53 million
Book Value:
0.183
Revenue TTM:
$342996
Operating Margin TTM:
-5372.83%
Gross Profit TTM:
$350711
Profit Margin:
0%
Return on Assets TTM:
-100.88%
Return on Equity TTM:
-281.76%

Company Profile

ABVC Biopharma Inc had its IPO on 2017-10-11 under the ticker symbol ABVC.

The company operates in the Healthcare sector and Biotechnology industry. ABVC Biopharma Inc has a staff strength of 28 employees.

Stock update

Shares of ABVC Biopharma Inc opened at $1.07 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.07 - $1.18, and closed at $1.13.

This is a +5.61% increase from the previous day's closing price.

A total volume of 21,548 shares were traded at the close of the day’s session.

In the last one week, shares of ABVC Biopharma Inc have slipped by -8.87%.

ABVC Biopharma Inc's Key Ratios

ABVC Biopharma Inc has a market cap of $21.53 million, indicating a price to book ratio of 4.08 and a price to sales ratio of 66.5973.

In the last 12-months ABVC Biopharma Inc’s revenue was $342996 with a gross profit of $350711 and an EBITDA of $-18407944. The EBITDA ratio measures ABVC Biopharma Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, ABVC Biopharma Inc’s operating margin was -5372.83% while its return on assets stood at -100.88% with a return of equity of -281.76%.

In Q3, ABVC Biopharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 57.3%.

ABVC Biopharma Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.72 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into ABVC Biopharma Inc’s profitability.

ABVC Biopharma Inc stock is trading at a EV to sales ratio of 75.3857 and a EV to EBITDA ratio of -1.46. Its price to sales ratio in the trailing 12-months stood at 66.5973.

ABVC Biopharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$10.48 million
Total Liabilities
$3.89 million
Operating Cash Flow
$-1523150.00
Capital Expenditure
$4357
Dividend Payout Ratio
0%

ABVC Biopharma Inc ended 2024 with $10.48 million in total assets and $0 in total liabilities. Its intangible assets were valued at $10.48 million while shareholder equity stood at $5.92 million.

ABVC Biopharma Inc ended 2024 with $0 in deferred long-term liabilities, $3.89 million in other current liabilities, 32632.00 in common stock, $-50040501.00 in retained earnings and $0.00 in goodwill. Its cash balance stood at $1.32 million and cash and short-term investments were $1.40 million. The company’s total short-term debt was $2,230,002 while long-term debt stood at $0.

ABVC Biopharma Inc’s total current assets stands at $2.90 million while long-term investments were $816160.00 and short-term investments were $77583.00. Its net receivables were $547680.00 compared to accounts payable of $0 and inventory worth $20489.00.

In 2024, ABVC Biopharma Inc's operating cash flow was $-1523150.00 while its capital expenditure stood at $4357.

Comparatively, ABVC Biopharma Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$1.13
52-Week High
$3.13
52-Week Low
$0.5
Analyst Target Price
$2.02

ABVC Biopharma Inc stock is currently trading at $1.13 per share. It touched a 52-week high of $3.13 and a 52-week low of $3.13. Analysts tracking the stock have a 12-month average target price of $2.02.

Its 50-day moving average was $2.78 and 200-day moving average was $5.89 The short ratio stood at 1.4 indicating a short percent outstanding of 0%.

Around 4002.6% of the company’s stock are held by insiders while 184.1% are held by institutions.

Frequently Asked Questions About ABVC Biopharma Inc

The stock symbol (also called stock or share ticker) of ABVC Biopharma Inc is ABVC

The IPO of ABVC Biopharma Inc took place on 2017-10-11

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$14.83
-0.12
-0.8%
$46.52
-2.07
-4.26%
$78.1
-2.1
-2.62%
$30.31
-1.59
-4.98%
$14.34
0.33
+2.36%
$37.46
0.36
+0.97%
$4.01
-0.02
-0.5%
$8.81
0.2
+2.32%
$77.75
-0.94
-1.19%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.

Address

44370 Old Warm Springs Boulevard, Fremont, CA, United States, 94538